Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2025 02:00 ET | Source: Averoa

AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)

The MHRA (Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval...
September 29, 2025 04:15 ET | Source: Research and Markets

2 Day Virtual Variations to Marketing Authorisations Training Course: Enhance Efficiency in Dossier Updates and Benefit from Expert Guidance on Filing Strategies (Oct 15th - Oct 16th, 2025)

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course (Oct 15th - Oct 16th, 2025)" training has been added to ResearchAndMarkets.com's offering. ...
June 16, 2025 06:00 ET | Source: Averoa

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International...
January 31, 2024 04:47 ET | Source: Research and Markets

2 Day Virtual Variations to Marketing Authorisations Training Course

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
May 31, 2023 09:19 ET | Source: Pharmazz, Inc.

Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients

The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
May 02, 2023 08:03 ET | Source: Research and Markets

Variations to Marketing Authorisations Training Course: Optimising Regulatory Procedures to Achieve Faster Approval

Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
December 28, 2021 18:15 ET | Source: The Rosen Law Firm PA

OWLT LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action – OWLT

NEW YORK, Dec. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (a) purchasers of the securities of Owlet, Inc. (NYSE: OWLT) between March 31, 2021 and...
August 06, 2021 04:53 ET | Source: Research and Markets

Global Orphan Drugs Market Report 2021-2026 Featuring Market Leaders - AbbVie, Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer and Sanofi-Aventis

Dublin, Aug. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The Global Orphan Drug Market is Set to Grow to $191...
January 12, 2021 09:28 ET | Source: Research and Markets

Global Rare Diseases Drug Development, Clinical Trials and the Regulatory Landscape Report 2021 with Analysis of Trends and Characteristics of Clinical Trials from 1999-2018

Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Drug Development in Rare Diseases: Focus on Clinical Trials and the Regulatory Landscape" report has been added to ResearchAndMarkets.com's offering....
April 30, 2020 20:14 ET | Source: Telix Pharmaceuticals Limited

Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product

MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...